Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback